Based on the discovery of a novel class of neuroplasticity-promoting therapeutics known as psychoplastogens, we are building a world class CNS company on a mission to broaden patient access to safe, fast-acting, and long-lasting medicines for many of the leading causes of disability worldwide.

Delix is pushing the frontiers of neuroplasticity research to achieve selective re-wiring of pathological neural circuits.  As dysfunctional neural circuits are at the heart of all brain disorders, the Delix platform has broad potential to address a range of diseases including treatment-resistant depression, substance use disorder, PTSD, cognitive impairment in schizophrenia, neurodegeneration, and many others. 

Using our platform, we are developing a pipeline of distinct therapeutic assets tailored to specific disease indications.  These include novel molecules inspired by the structures of psychedelics that positively re-wire pathological neural circuitry, but without the hallucinogenic and other side effects that have prevented ketamine and psychedelics from being deployed at scale.

Our scientific rigor has enabled us to build broad screening capabilities that include gold standard assays as well as innovative, cutting-edge technologies. With several partners and alliances, we are advancing over 500 compounds based on > 8 unique chemical scaffolds.  Our first two assets are on track to be in the clinic in 2022, with several additional compounds not far behind.